Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The effect of adenovirus-mediated gene expression of FHIT in small cell lung cancer cells

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Cetuximab insufficiently inhibits glioma cell growth due to persistent EGFR downstream signaling

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Gel-Based Proteomics of Clinical Samples Identifies Potential Serological Biomarkers for Early Detection of Colorectal Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Evaluation of algorithm development approaches: Development of biomarker panels for early detection of colorectal lesions

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Prognostic factors for relapse in patients with clinical stage I testicular cancer: protocol for a Danish nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Predictive biomarkers and prognostic models are required to identify recurrent grade III glioma patients who benefit from existing treatment. In this study of 62 recurrent grade III glioma patients, a range of clinical and paraclinical factors are tested for association with progression-free survival, overall survival, and response to bevacizumab and irinotecan therapy. Significant factors from univariate screening are included in multivariate analysis. Biomarkers previously advanced as predictive or prognostic in the first-line setting did not affect outcome in this patient cohort. Based on the optimized model for overall survival, comprising performance status and p53 expression, a prognostic index is established.

Original languageEnglish
JournalCancer Investigation
Volume36
Issue number2
Pages (from-to)165-174
ISSN0735-7907
DOIs
Publication statusPublished - 2018

    Research areas

  • Journal Article

ID: 52644778